Literature DB >> 26851803

One good DNA-damage deserves another: Oxaliplatin in MSI-high colon cancer.

Howard S Hochster1, Daniel J Sargent2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26851803     DOI: 10.1093/jnci/djw011

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  2 in total

1.  Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair.

Authors:  Huabin Hu; Zehua Wu; Chao Wang; Yan Huang; Jianwei Zhang; Yue Cai; Xiaoyu Xie; Jianxia Li; Cailu Shen; Weiwei Li; Jiayu Ling; Xuehu Xu; Yanhong Deng
Journal:  Front Oncol       Date:  2020-12-04       Impact factor: 6.244

2.  The SOX9-MMS22L Axis Promotes Oxaliplatin Resistance in Colorectal Cancer.

Authors:  Yiqiang Liu; Hong Wu; Tao Luo; Qiyu Luo; Ziyu Meng; Ying Shi; Feifei Li; Mingxin Liu; Xinhao Peng; Junjie Liu; Chuan Xu; Weizhong Tang
Journal:  Front Mol Biosci       Date:  2021-05-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.